Collegium Pharmaceutical, Inc. (COLL) Q3 2026 earnings results
Collegium Pharmaceutical, Inc. (COLL) reported Q3 2026 results on Nov 5, 2026, 7:32:59 AM ET: adjusted EPS $1.96 vs. $1.86 expected (beat by 5.6%); revenue $216.34M vs. $216.03M expected (beat by 0.1%). Outlook: The Company reaffirms its full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net, AZSTARYS Revenue, Net and Adjusted EBITDA.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $1.96 | $1.86 | Beat by 5.6% |
| Revenue | $216.34M | $216.03M | Beat by 0.1% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 7:32:59 AM ET. Nexqual published them 33 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 3.3% from $209.36M.
Stock reaction
The results came out before the market opened. COLL closed at $25.16 on November 5, 2026, up 6.3% from its $23.67 close on November 4, 2026 before the results. Latest: $24.25 as of 11:46 AM ET, +2.5% since the pre-release close.
Questions and answers
Did Collegium Pharmaceutical, Inc. beat earnings expectations?
Yes. Collegium Pharmaceutical, Inc. reported adjusted EPS of $1.96 against an average analyst estimate of $1.86 (beat by 5.6%), and revenue of $216.34M against $216.03M expected (beat by 0.1%).
What were Collegium Pharmaceutical, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $1.96 and revenue of $216.34M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 3.3% from $209.36M.
When did Collegium Pharmaceutical, Inc. report Q3 2026 earnings?
Nov 5, 2026, 7:32:59 AM ET, in an SEC 8-K filing (Item 2.02).
How did COLL stock react to the earnings?
The results came out before the market opened. COLL closed at $25.16 on November 5, 2026, up 6.3% from its $23.67 close on November 4, 2026 before the results. Latest: $24.25 as of 11:46 AM ET, +2.5% since the pre-release close.
What did Collegium Pharmaceutical, Inc. say about its outlook?
The Company reaffirms its full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net, AZSTARYS Revenue, Net and Adjusted EBITDA.
More on COLL
COLL stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:46 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:46 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt